Safe breastfeeding allergy medications are available for most common allergic conditions, including hay fever, allergic rhinitis, urticaria, and eczema. Managing these conditions whilst nursing requires careful medication selection, as some drugs pass into breast milk and may affect a nursing infant. Fortunately, several well-evidenced options — including non-sedating antihistamines and intranasal corticosteroid sprays — are considered compatible with breastfeeding under UK clinical guidance. This article outlines which allergy treatments are recommended, which to avoid, and when to seek advice from a GP or pharmacist.

Managing Allergies While Breastfeeding in the UK

Most mild-to-moderate allergic conditions can be managed safely during breastfeeding by selecting medications with favourable safety profiles and using the lowest effective dose for the shortest necessary duration.

Allergic conditions — including hay fever, allergic rhinitis, urticaria (hives), and eczema — are extremely common in the UK, affecting millions of adults. For breastfeeding mothers, managing these conditions requires careful consideration, as many medications can pass into breast milk in varying quantities and may potentially affect a nursing infant.

The good news is that most mild-to-moderate allergic conditions can be managed safely during breastfeeding, provided the right medications are chosen. The key principle is to use the lowest effective dose for the shortest necessary duration, and to select agents with the most favourable safety profiles for lactating women. For medicines with a short half-life, taking the dose immediately after a feed — rather than just before — can help minimise the amount that passes into breast milk during the next feed.

The guidance in this article applies primarily to mothers of healthy, full-term infants. If your baby was born prematurely, is jaundiced, or has any medical condition, seek specialist advice before taking any medication, as recommendations may differ.

It is important to note that untreated allergies can affect a mother's wellbeing, sleep quality, and ability to care for her baby. The decision to treat should therefore weigh the benefits to the mother against any theoretical risk to the infant. In most cases, the benefits of treatment — and of continued breastfeeding — outweigh the risks associated with appropriate allergy medication use. Mothers should always seek personalised advice from a GP or pharmacist before starting any new medication whilst breastfeeding. The NHS 'Breastfeeding and medicines' overview is a useful patient-facing starting point.

Which Allergy Medications Are Considered Safe During Breastfeeding

Topical treatments such as intranasal corticosteroids and antihistamine eye drops are preferred first-line options, with loratadine and cetirizine recommended as safe oral antihistamines during breastfeeding.

Several allergy medications are generally considered compatible with breastfeeding based on available evidence, pharmacological properties, and guidance from UK and European regulatory bodies, including the UK Specialist Pharmacy Service (SPS) and its UK Drugs in Lactation Advisory Service (UKDILAS).

Topical and locally acting treatments are typically preferred as first-line options because they minimise systemic absorption and therefore reduce the amount of drug that may enter breast milk:

• Intranasal corticosteroid sprays (e.g., fluticasone, mometasone, budesonide, beclometasone) — widely regarded as compatible with breastfeeding; systemic absorption and milk transfer are negligible (see section below for agent-specific detail)

• Topical antihistamine or mast cell stabiliser eye drops (e.g., sodium cromoglicate, ketotifen, olopatadine) — considered low risk due to negligible systemic absorption

• Emollients and mild topical corticosteroids for eczema management — generally safe when applied to limited skin areas; if a low-potency topical corticosteroid is needed on or near the nipple, apply it after a feed and gently wipe the area clean before the next feed

Non-sedating oral antihistamines such as loratadine (10 mg once daily) and cetirizine (10 mg once daily) are the preferred oral options. Both have relatively low transfer into breast milk and are not expected to cause sedation or adverse effects in a healthy, full-term infant at standard doses. Loratadine is often cited as the antihistamine of choice during breastfeeding in UK clinical practice. Fexofenadine is an additional non-sedating option considered compatible with breastfeeding by SPS/UKDILAS when clinically appropriate. Wherever possible, choose single-ingredient products rather than combination remedies.

Experiencing these side effects? Our pharmacists can help you navigate them →

Sodium cromoglicate nasal spray is another option with a well-established safety profile. It is a mast cell stabiliser — not an antihistamine — that acts locally to prevent the release of histamine and other inflammatory mediators. Because it is poorly absorbed systemically, transfer into breast milk is considered negligible.

Antihistamines and Nasal Sprays: What the Evidence Shows

Loratadine has the strongest evidence base, with a relative infant dose below 2%; all four commonly used intranasal corticosteroids are supported by SPS guidance as compatible with breastfeeding.

The evidence base for antihistamine use during breastfeeding is largely reassuring, particularly for second-generation (non-sedating) antihistamines. Loratadine has been the most extensively studied in breastfeeding populations. The relative infant dose (RID) — the weight-adjusted proportion of the maternal dose received by the infant via breast milk — is estimated at less than 1–2%, well below the 10% threshold generally considered of concern. No adverse effects in breastfed infants have been reported in the published literature.

Cetirizine is similarly well-tolerated. Although data are more limited than for loratadine, cetirizine is considered compatible with breastfeeding by SPS/UKDILAS and is listed as acceptable in most UK formulary references. Both loratadine and cetirizine are available over the counter in the UK, making them accessible options for nursing mothers. Fexofenadine is also considered acceptable by SPS/UKDILAS as an alternative non-sedating antihistamine.

For nasal symptoms, intranasal corticosteroid sprays are considered first-line pharmacological treatment for allergic rhinitis in breastfeeding women, in line with NICE CKS guidance. The systemic bioavailability of these agents varies: fluticasone propionate and mometasone furoate have very low systemic availability (typically less than 1–2%), whilst budesonide and beclometasone have somewhat higher systemic absorption. However, all four agents undergo extensive first-pass hepatic metabolism, and the amount reaching breast milk is considered negligible for each. SPS guidance supports the use of all four agents during breastfeeding. Fluticasone propionate (e.g., Flixonase) and beclometasone (e.g., Beconase) are available over the counter; mometasone and budesonide are available on prescription.

Saline nasal rinses and allergen avoidance strategies remain important non-pharmacological adjuncts that carry no risk to the breastfed infant and should be encouraged alongside any medication.

Medications to Use With Caution or Avoid When Breastfeeding

Sedating antihistamines, pseudoephedrine, and oral decongestants should be avoided or used only with medical supervision, as they carry risks of infant sedation, reduced milk supply, or inadequate safety data.

Whilst many allergy medications are safe, some should be used with caution or avoided altogether during breastfeeding.

First-generation (sedating) antihistamines — such as chlorphenamine (e.g., Piriton) and promethazine — are generally not recommended as first-line options for breastfeeding mothers. These older antihistamines cross the blood-brain barrier more readily and may cause:

• Sedation or drowsiness in the nursing infant

• Irritability or poor feeding in some cases

• Respiratory depression — a rare but serious concern, particularly in premature or very young infants

If a sedating antihistamine is used short-term when no suitable alternative is available, the smallest effective dose should be taken and the infant monitored closely for excessive sleepiness, poor feeding, or unusual irritability. This should only be under medical supervision. Promethazine is specifically contraindicated in infants under two years of age and should be avoided by breastfeeding mothers.

Oral decongestants require careful consideration. Pseudoephedrine should be avoided: it has been shown to reduce milk supply and may cause irritability in breastfed infants. Phenylephrine is generally not recommended during breastfeeding due to limited safety data. If a decongestant is genuinely needed for short-term nasal congestion, a topical nasal decongestant (e.g., xylometazoline or oxymetazoline nasal spray) used for no more than a few days is considered a lower-risk alternative, as systemic absorption is minimal. Many over-the-counter combination cold and allergy remedies contain oral decongestants, so mothers should always check labels carefully and seek pharmacist advice.

Oral corticosteroids (e.g., prednisolone) are occasionally required for severe allergic reactions. Short courses at doses up to approximately 40 mg per day are generally considered compatible with breastfeeding. At higher doses or with prolonged use, consider delaying breastfeeding for around four hours after each dose to reduce infant exposure, and seek specialist review. Allergen immunotherapy (desensitisation) is not typically initiated during breastfeeding, though ongoing treatment may be continued under specialist guidance.

NHS and MHRA Guidance on Allergy Treatment for Nursing Mothers

NICE recommends intranasal corticosteroids as first-line treatment for allergic rhinitis in breastfeeding women; SPS/UKDILAS provides more nuanced lactation assessments than standard SmPC documents.

In the UK, guidance on medication use during breastfeeding is informed by several authoritative sources, including the Medicines and Healthcare products Regulatory Agency (MHRA), the electronic Medicines Compendium (emc), NICE clinical guidelines, and the UK Drugs in Lactation Advisory Service (UKDILAS), accessed via the UK Specialist Pharmacy Service (SPS).

NICE guidance on allergic rhinitis (CKS: Allergic rhinitis) recommends intranasal corticosteroids as first-line pharmacological treatment for persistent or moderate-to-severe symptoms, with non-sedating antihistamines as an adjunct or alternative for mild intermittent symptoms. These recommendations apply broadly to breastfeeding women, with the caveat that individual clinical judgement and patient preference should guide prescribing.

The MHRA advises that product Summary of Product Characteristics (SmPC) documents, available via the emc, should be consulted for specific lactation data. It is worth noting that many SmPCs adopt a cautious default position — advising avoidance during breastfeeding — due to limited clinical trial data in this population, rather than evidence of actual harm. SPS/UKDILAS and the Breastfeeding Network's Drugs in Breastmilk service provide more nuanced, evidence-based assessments that are often more helpful in clinical practice.

The NHS recommends that breastfeeding mothers consult a pharmacist or GP before taking any over-the-counter allergy medication, as formulations and ingredients vary widely. NHS medicines pages for loratadine, cetirizine, and steroid nasal sprays provide accessible patient-facing reassurance. Mothers are encouraged to use these resources proactively rather than stopping breastfeeding unnecessarily.

Still have questions? Message our pharmacists for free →

If you or your baby experience a suspected side effect from any medication, please report it via the MHRA Yellow Card scheme (available at yellowcard.mhra.gov.uk). This applies to side effects in both the mother and the breastfed infant.

When to Seek Advice From a GP or Pharmacist

Seek professional advice if symptoms are severe, if your infant shows signs of drowsiness or poor feeding after a new medication, or if you require combination products or oral corticosteroids.

Whilst many allergy medications can be safely self-managed with over-the-counter products, there are several situations in which breastfeeding mothers should seek professional advice before or during treatment.

Consult a GP or pharmacist if:

• You are unsure whether a specific medication is safe to use whilst breastfeeding

• Your allergy symptoms are severe, persistent, or significantly affecting your daily functioning or sleep

• You are considering taking a combination product (e.g., a cold and flu remedy) that may contain multiple active ingredients, including oral decongestants

• Your infant appears unusually drowsy, is difficult to rouse, is feeding poorly, has a poor latch, or is not gaining weight as expected after you have started a new medication

• You require oral corticosteroids or have been prescribed a medication not covered by standard over-the-counter guidance

• You have a history of anaphylaxis or carry an adrenaline auto-injector (e.g., EpiPen) — emergency treatment with adrenaline is always appropriate regardless of breastfeeding status

Call 999 or go to A&E immediately if you or your baby experience signs of a severe allergic reaction (anaphylaxis), including swelling of the face, lips, or throat, difficulty breathing, or collapse. Do not delay emergency treatment.

Pharmacists in the UK are highly trained and accessible without an appointment, making them an excellent first point of contact for medication queries. The Breastfeeding Network's Drugs in Breastmilk helpline, SPS/UKDILAS, and NHS 111 can also provide guidance outside of GP hours. If you or your baby experience a suspected adverse reaction to any medication, report it via the MHRA Yellow Card scheme. The overarching message is clear: safe breastfeeding allergy medications exist, and with the right advice, most mothers can manage their symptoms effectively without compromising their baby's health or their breastfeeding journey.

Frequently Asked Questions